Why Oncternal's Stock Is Trading Lower Today

Oncternal Therapeutics (NASDAQ: ONCT) shares are trading lower on Wednesday after the company announced an increase in its previously announced bought deal offering to 7.25 million shares at $3.10 per share.

Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. Its product pipeline includes Cirmtuzumab, TK216, and ROR1 CAR-T.

Oncternal Therapeutics shares were trading down 29.95% at $2.90 at last check Wednesday. The stock has a 52-week range between $6.28 and $1.49.